Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT01304797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Study identification
- NCT ID
- NCT01304797
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
- MM-302 Monotherapy Drug
- MM-302 in combination with trastuzumab Drug
- MM-302 in combination with trastuzumab q3w Drug
- MM-302 in combination with trastuzumab and cyclophosphamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Jul 31, 2016
- Completion
- Dec 31, 2016
- Last update posted
- Jan 5, 2017
2011 – 2017
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | — | — |
| University of Indiana | Indianapolis | Indiana | — | — |
| Dana Farber Cancer Center | Boston | Massachusetts | — | — |
| Karmanos Cancer Center | Detroit | Michigan | — | — |
| Washington University | St Louis | Missouri | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01304797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01304797 live on ClinicalTrials.gov.